The company offers synthetic DNA manufacturing services for genes, oligonucleotide pools, and variant libraries.
The firm is looking to edit pigs with CRISPR/Cas9 to create organs and tissues that can be transplanted into humans.
The funding will help the company accelerate the commercialization of its proprietary genome-editing technology.
The company sold shares, convertible debentures, and warrants to an institutional investor as part of a previously announced deal.
The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
The Silicon Valley startup has launched with a proprietary automation platform, and counts CRISPR researcher Jennifer Doudna among its new investors.
The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.
The food safety firm is using NGS testing and data analytics to create actionable information for retailers and manufacturers.
The company plans to use the new funding to expand into Asia, with a particular focus on China.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.